Antipsychotics · Second-Generation (Atypical)
Paliperidone
Brand: Invega (oral ER), Invega Sustenna (monthly LAI), Invega Trinza (every-3-month LAI), Invega Hafyera (every-6-month LAI)
Second-generation antipsychotic (SGA) / Atypical antipsychotic, benzisoxazole derivative
12 cards
Want adaptive tracking?
Create a free account and every review is tracked with spaced repetition. Cards you struggle with come back sooner, and your weak areas surface automatically.
Create free account →Card Topics
core (2)dosing (3)trap (3)monitoring (1)risk (2)population (1)
All Cards
1.Paliperidone: relationship to risperidone and pharmacokinetic advantage.
2.Paliperidone LAI formulations and intervals.
3.Invega Sustenna loading dose protocol.
4.Can Invega Sustenna loading doses be given in the gluteal?
5.Renal dosing for paliperidone.
6.Prolactin effects of paliperidone.
7.Patient misses Sustenna dose by 6+ weeks. What happens?
8.Invega Trinza eligibility requirement.
9.Invega Hafyera eligibility.
10.Missed Sustenna dose management by timing.
11.Paliperidone in renal impairment.
12.Patient switching from oral risperidone to Sustenna — need oral overlap?
Want the full clinical reference for this medication?
Read the Paliperidone reference page →